Quick Takeaways
- Commodore Capital LP filed SCHEDULE 13G/A for Nurix Therapeutics, Inc. Common Stock, par value $0.001 per share (NRIX).
- Disclosed ownership: 4.9%.
- Date of event: 30 Sep 2025.
Commodore Capital LP - 30 Sep 2025 SCHEDULE 13G/A Report for Nurix Therapeutics, Inc. Common Stock, par value $0.001 per share (NRIX)
- Filing Manager
- Commodore Capital LP
- Reporting Manager
- Commodore Capital LP
- Symbol
- NRIX
- Shares outstanding
- 77,143,980 shares
- Disclosed Ownership
- 3,780,055 shares
- Ownership
- 4.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Nov 2025, 17:02:01 UTC
- Date of event
- 30 Sep 2025
- Previous filing
- 14 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Commodore Capital LP disclosed 4.9% ownership in Nurix Therapeutics, Inc. Common Stock, par value $0.001 per share (NRIX) on 30 Sep 2025."
What Changed
- Previous schedule filing date: 14 Feb 2025.
- Current filing was accepted on 14 Nov 2025, 17:02.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Commodore Capital LP | 4.9% | 3,780,055 | 0 | 3,780,055 | Michael Kramarz | Managing Partner | |
| Commodore Capital Master LP | 4.9% | 3,780,055 | 0 | 3,780,055 | Michael Kramarz | Authorized Signatory |